Journal: Mediterranean Journal of Rheumatology

Article Title: Theory-informed interventions to promote physical activity and reduce sedentary behaviour in rheumatoid arthritis: a critical review of the literature

doi: 10.31138/mjr.31.1.19

Figure Lengend Snippet: Details of interventions promoting physical activity engagement or reducing sedentary behaviour in RA; study aim, design and content, participant characteristics, methodology and results.

Article Snippet: Gilbert et al., 2018 RCT - to test the efficacy of the IMPAACT intervention for persons with RA (and OA) in improving arthritis-specific and generic self-reported pain and physical function outcomes, observed measures of function, and objectively measured and self-reported PA levels. , IG (n = 93) vs. CG (n = 92) IG = brief physician recommendation to increase PA to meet national guidelines + motivational interviewing for PA at baseline, 3, 6 and 12-months (year 1, + 2 × sessions in year 2). CG = brief physician recommendation to increase PA to meet national guidelines. Length of intervention: 2 years , 1. 55 ± 14 (IG) 55 ± 14 (CG) 2. 13 ± 10 (IG) 13 ± 10 (CG) 3. 84% , OB: GT1M Actigraph accelerometer (7 day wear, 60 second epochs, valid wear requirement; >=4 days with >= 10 hours wear/day. MVPA, >=2020 accelerometer counts/min (Troiano et al., 2008). Cut-points not validated for use in RA SR: Yale Physical Activity Scale. Report time in PA during a typical week from the past month, and overall estimates of PA over the entire past month. Some evidence for validity in RA. Assessments: baseline, 3, 6, 12, 18 and 24 months. , Moderate to vigorous PA (OB) - no significant differences between IG and CG. 1) total time index; 2) energy expenditure index; 3) activity dimensions summary Index (SR) - no significant differences between IG and CG..

Techniques: Activity Assay, Biomarker Discovery

Journal: Drug Design, Development and Therapy

Article Title:

In vivo Screening of Natural Products Against Angiogenesis and Mechanisms of Anti-Angiogenic Activity of Deoxysappanone B 7,4ʹ-Dimethyl Ether

doi: 10.2147/dddt.s252681

Figure Lengend Snippet: Figure 1 Representative bright-field (A, D, G, J and M) and fluorescent (B, E, H, K and N) images of 24 h post-fertilization zebrafish embryos exposed to 0.1% dimethyl sulfoxide (control), 10 μM lead compounds, or 5 μM PTK787 for 24 h (magnification ×40). The images of (C, F, I, L and O) (magnification ×112.5) are the subset of the images B, E, H, K, N, respectively. Asterisks indicate occasional sprouts of DA. Scar bar = 200 μm; Deox B 7,4, Deoxysappanone B 7,4ʹ-Dimethyl Ether. Abbreviations: DLAV, dorsal longitudinal anastomotic vessels; ISVs, intersegmental vessels; DA, dorsal aorta; PCV, posterior cardinal vein.

Article Snippet: PTK787 (5 μM, Selleck Chemicals, submit your manuscript | www.dovepress.com DovePress Drug Design, Development and Therapy 2020:143070 D ru g D es ig n, D ev el op m en t a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .d ov ep re ss .c om / b y 84 .5 4.

Techniques: Control

Journal: Drug Design, Development and Therapy

Article Title:

In vivo Screening of Natural Products Against Angiogenesis and Mechanisms of Anti-Angiogenic Activity of Deoxysappanone B 7,4ʹ-Dimethyl Ether

doi: 10.2147/dddt.s252681

Figure Lengend Snippet: Figure 3 Representative bright-field (A–E) and fluorescent (F–J) images of 24 h post-fertilization zebrafish embryos exposed to 0.1% dimethyl sulfoxide (control), 1 μM, 2.5 μM, or 5 μM Deox B 7,4, or 5 μM PTK787 for 24 h (magnification ×40). The image of (K–O) (magnification ×112.5) is a subset of the image of (F–J), respectively. Asterisks indicate occasional sprouts of DA. (P) The number of complete ISVs in embryos treated with dimethyl sulfoxide, Deox B 7,4, or PTK787. (Q) The inhibition rate of complete ISVs in Deox B 7,4-treated embryos. Values have been displayed as mean ± standard error of the mean (n=10). ***P <0.001. Scar bar = 200 μm; Deox B 7,4, Deoxysappanone B 7,4ʹ-Dimethyl Ether. Abbreviations: DLAV, dorsal longitudinal anastomotic vessels; ISVs, intersegmental vessels; DA, dorsal aorta; PCV, posterior cardinal vein.

Article Snippet: PTK787 (5 μM, Selleck Chemicals, submit your manuscript | www.dovepress.com DovePress Drug Design, Development and Therapy 2020:143070 D ru g D es ig n, D ev el op m en t a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .d ov ep re ss .c om / b y 84 .5 4.

Techniques: Control, Inhibition

Journal: Drug Design, Development and Therapy

Article Title:

In vivo Screening of Natural Products Against Angiogenesis and Mechanisms of Anti-Angiogenic Activity of Deoxysappanone B 7,4ʹ-Dimethyl Ether

doi: 10.2147/dddt.s252681

Figure Lengend Snippet: Figure 4 Expression profiles of angiogenesis-related genes in 24 h post-fertilization zebrafish embryos treated with 0.1% dimethyl sulfoxide (control), 5 μM Deox B 7,4, or 5 μM PTK787 for 24 h. Values have been displayed as mean ± standard error of the mean (n=4). **P <0.01 vs control, ***P <0.001 vs control. ns, not significant. Abbreviations: vegfaa, vascular endothelial growth factor Aa; vegfr, vascular endothelial growth factor receptor; fgfr, fibroblast growth factor receptor; COX-2, cyclooxygenase-2; mmp9, matrix metallopeptidase 9; ptp-rb, protein tyrosine phosphatase, receptor type B; pik3r2, phosphoinositide-3-kinase regulatory subunit 2; slit, slit guidance ligand; robo, roundabout guidance receptor; dll4, delta-like ligand 4; notch1a, neurogenic locus notch homolog protein 1; hey2, Hes-related family basic helix- loop-helix transcription factor with YRPW motif 2; efnb2, ephrin B2.

Article Snippet: PTK787 (5 μM, Selleck Chemicals, submit your manuscript | www.dovepress.com DovePress Drug Design, Development and Therapy 2020:143070 D ru g D es ig n, D ev el op m en t a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .d ov ep re ss .c om / b y 84 .5 4.

Techniques: Expressing, Control